Additional Description:
Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. is a technology-driven company delivering innovative solutions for the pharmaceutical and advanced materials industries. Rather than acting as a standard vendor, it positions itself as a technical partner capable of solving complex synthetic challenges that conventional suppliers cannot handle, with core expertise spanning custom synthesis of complex molecules, R&D and production of high-end precious metal catalysts, and reliable supply of high-purity pharmaceutical intermediates. Through a dual "in-house manufacturing plus globally curated sourcing" model, the company pairs technical excellence with supply chain resilience to support clients from discovery through commercialization. Its technical strengths include manufacturing highly difficult compounds - deuterated chemicals with isotopic purity of 99.8% or higher, high-purity epoxides with metal impurities below 1ppm, and sophisticated precious metal catalysts comparable to products like UMICORE M51 - with several proprietary innovations under patent application. A ten-scientist in-house R&D team collaborates with institutions such as the University of Shanghai for Science and Technology, Zhejiang University and the Shanghai Institute of Organic Chemistry, enabling smooth scale-up of complex molecules from lab synthesis to commercial production. An in-house analytical laboratory equipped with GC, HPLC, HNMR and GC-MS instruments enforces rigorous quality control on every batch, whether produced internally or sourced through the company's curated global supplier network - a network its experienced sourcing team uses to identify, vet and manage high-quality partners worldwide, offering a one-stop procurement service that reduces supply chain risk. Core offerings include key intermediates for blockbuster drugs such as deucravacitinib, finerenone, vericiguat and orforglipron, produced at commercial scale with proven quality; a range of precious metal catalysts from standard products like ruthenium(III) chloride, palladium on carbon, palladium(II) acetate and platinum(IV) oxide to complex custom catalysts for asymmetric synthesis and green chemistry; and high-purity epoxide monomers such as 1,2-epoxydodecane, 1,2-epoxytetradecane and 1,2-epoxyhexadecane serving the high-end polymer and liquid crystal material sectors.
Leave your rating & comment